North Carolina Bids > Bid Detail

Notice of Intent to Award Sole Source: Antiviral Medicine – Zanamivir (Relenza®)

Agency:
Level of Government: Federal
Category:
  • 65 - Medical, Dental, and Veterinary Equipment and Supplies
Opps ID: NBD00159723112895866
Posted Date: Feb 28, 2024
Due Date: Mar 13, 2024
Source: https://sam.gov/opp/97a55b5ed9...
Follow
Notice of Intent to Award Sole Source: Antiviral Medicine – Zanamivir (Relenza®)
Active
Contract Opportunity
Notice ID
Related Notice
Department/Ind. Agency
HOMELAND SECURITY, DEPARTMENT OF
Sub-tier
OFFICE OF PROCUREMENT OPERATIONS
General Information View Changes
  • Contract Opportunity Type: Special Notice (Updated)
  • All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Updated Published Date: Feb 28, 2024 06:34 am EST
  • Original Published Date: Feb 27, 2024 09:14 am EST
  • Updated Response Date: Mar 13, 2024 02:00 pm EDT
  • Original Response Date: Mar 13, 2024 02:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Updated Inactive Date: Mar 28, 2024
  • Original Inactive Date: Mar 28, 2024
  • Initiative:
    • None
Classification View Changes
  • Original Set Aside:
  • Product Service Code: 6505 - DRUGS AND BIOLOGICALS
  • NAICS Code:
    • 325412 - Pharmaceutical Preparation Manufacturing
  • Place of Performance:
    Durham , NC 27701
    USA
Description

This is a notice of intent to award a Firm Fixed Price (FFP), sole source purchase order to GlaxoSmithKline (GSK), 410 Blackwell St, Durham, NC 27701-3986 pursuant to Federal Acquisition Regulation (FAR) subpart 13.5, Simplified Procedures for Certain Commercial Products and Commercial Services. Department of Homeland Security (DHS), Office of Procurement Operations (OPO), Office of Health Security (OHS) has a requirement in support of the Department’s Pandemic Workforce Preparedness Plan (PWPP) entitled “Antiviral Medicine—Zanamivir (Relenza)”. Market research for this acquisition, demonstrated that GSK is the only commercially available, that has been authorized by the FDA, to manufacture Relenza. The basic requirement is to: acquire the antiviral medicine, Zanamivir - Relenza®, for the DHS antiviral stockpile to prepare for a highly pathogenic outbreak that could lead to a pandemic. The Period of Performance for this requirement is one 12-month base period, four consecutive 12-month option periods. More details can be found in the Statement of Work (SOW) under “Attachments”. The estimated total dollar value of this contract is $1,900,000.00.





Possible interested parties responding to this notice must show clear and convincing evidence that it possesses a solution with the technical capability to satisfy the requirement listed in Section 6 of the SOW are encouraged to reply to this notice to the points-of-contact below no later than March 13, 2024, 2:00 p.m. EST. Please ensure your response includes your company's name, a detailed technical capability statement and any other information that demonstrates their ability to meet the needs of the Government, UEI number, and point-of-contact name and email. Responses are limited to no more than five pages. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.


Attachments/Links
Contact Information
Primary Point of Contact
Secondary Point of Contact
History

TRY FOR FREE

Not a USAOPPS Member Yet?

Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.

Start Free Trial Today >